# EDGAR Filing Document

**Accession Number:** 0001831828
**File Stem:** 0001104659-26-023756
**Filing Date:** 2026-3
**Character Count:** 29074
**Document Hash:** 14b9072e36a98b97c401c1ac1a7a85be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-023756.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001104659-26-023756

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001831828
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812744449
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92556
- **FILM NUMBER:** 26724087

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY, SUITE 1200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 650-770-0077

**MAIL ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY, SUITE 1200
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sofinnova Venture Partners X, L.P.
- **CENTRAL INDEX KEY:** 0001680200

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-681-8420

**MAIL ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

## Ex-99.A

<u>exhibit A</u>

<u>Agreement of Joint Filing</u>

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Vera Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

Date: February 13, 2023

---

| | |
|:---|:---|
| SOFINNOVA VENTURE PARTNERS X, L.P., a Delaware Limited Partnership | SOFINNOVA VENTURE PARTNERS X, L.P., a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT X, L.P., a Delaware Limited Partnership |
| Its: | General Partner |
| By: | SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT X, L.P., a Delaware Limited Partnership | SOFINNOVA MANAGEMENT X, L.P., a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company | SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| DR. JAMES I. HEALY | DR. JAMES I. HEALY |
| DR. MAHA KATABI | DR. MAHA KATABI |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |

---

## Ex-99.B

<u>exhibit B</u>

**<u>Power of Attorney</u>**

Nathalie Auber has signed this Schedule 13D as Attorney-In-Fact. Note that copies of the applicable Power of Attorney are already on file with the appropriate agencies.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Vera Therapeutics, Inc.**

*(Name of Issuer)*

**Class A Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**92337R101**

*(CUSIP Number)*

**Nathalie Auber**<br>Sofinnova Investments, Inc.<br>3000 Sand Hill Road, Bldg 3, Suite 150<br>Menlo Park CA 94025<br>(650) 681-8420

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **92337R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Venture Partners X, L.P. ("SVP X")** | Name of reporting person<br>**Sofinnova Venture Partners X, L.P. ("SVP X")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.9%** | Percent of class represented by amount in Row (11)<br>**3.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7: 2,793,987 shares, except that Sofinnova Management X, L.P. ("SM X LP"), the general partner of SVP X, may be deemed to have sole voting power, Sofinnova Management X-A, L.L.C. ("SM X LLC"), the general partner of SM X LP, may be deemed to have sole voting power, and Dr. James I. Healy ("Healy") and Dr. Maha Katabi ("Katabi"), the managing members of SM X LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 2,793,987 shares, except that SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **92337R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management X, L.P. ("SM X LP")** | Name of reporting person<br>**Sofinnova Management X, L.P. ("SM X LP")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.9%** | Percent of class represented by amount in Row (11)<br>**3.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **92337R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management X-A, L.L.C. ("SM X LLC")** | Name of reporting person<br>**Sofinnova Management X-A, L.L.C. ("SM X LLC")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.9%** | Percent of class represented by amount in Row (11)<br>**3.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Note to Row 7: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared dispositive power over these shares.
.
Note to Row 10: See response to row 9.

| **CUSIP No.** | **92337R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2793987.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | Aggregate amount beneficially owned by each reporting person<br>**2793987.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.9%** | Percent of class represented by amount in Row (11)<br>**3.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 8: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Healy, a managing member of SM X LLC, may be deemed to have shared voting power to vote these shares.

Note to Row 10: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy, a managing member of SM X LLC, may be deemed to have shared dispositive power over these shares.

| **CUSIP No.** | **92337R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. Maha Katabi ("Katabi")** | Name of reporting person<br>**Dr. Maha Katabi ("Katabi")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**53850.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2793987.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**53850.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2793987.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2847837.00** | Aggregate amount beneficially owned by each reporting person<br>**2847837.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 7: 53,850 shares, all of which are subject to stock options exercisable by Katabi within 60 days of the date of this filing.

Note to Row 8: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Katabi, a managing member of SM X LLC and a director of the Issuer, may be deemed to have shared voting power to vote these shares.

Note to Row 9: 53,850 shares, all of which are subject to stock options exercisable by Katabi within 60 days of the date of this filing.

Note to Row 10: 2,793,987 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Katabi, a managing member of SM X LLC and a director of the Issuer, may be deemed to have shared dispositive power over these shares.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, $0.001 par value

**(b) Name of Issuer:**
Vera Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2000 Sierra Point Parkway, Suite 1200, Brisbane, CA, 94005

This Amendment No. 5 ("Amendment No. 5") amends and restates the Statement on Schedule 13D that was initially filed on May 24, 2021 and amended on February 6, 2023, February 14, 2023, February 20, 2024 and March 26, 2024 (as amended, the "Original Schedule 13D").  This Amendment No. 5 relates to the beneficial ownership of Class A Common Stock, $0.001 par value per share ("Common Stock") of Vera Therapeutics, Inc., a Delaware corporation ("Issuer") by Sofinnova Venture Partners X, L.P., a Delaware limited partnership ("SVP X"), Sofinnova Management X, L.P., a Delaware limited partnership ("SM X LP"), Sofinnova Management X-A, L.L.C., a Delaware limited liability company ("SM X LLC"), Dr. James I. Healy ("Healy"), and Dr. Maha Katabi ("Katabi" and collectively with SVP X, SM X LP, SM X LLC, and Healy, the "Reporting Persons").  This Amendment No. 5 is being filed to update the aggregate percentage of Common Stock owned by the Reporting Persons due to dilution caused by the Issuer's sales of additional shares of its Common Stock from time to time since the filing of the Original Schedule 13D.  In addition, the Issuer reported outstanding Common Stock in the Issuer's Form 424(b)(5) filed with the Securities and Exchange Commission on December 10, 2025 (File No. 333-282861), causing the Reporting Persons to cease to be beneficial owners of more than five percent (5%) of the Issuer's Common Stock as of September 30, 2025.

(a) The class of equity securities to which this statement relates is the Common Stock of the Issuer.

(b) The Issuer's principal executive offices are located at 2000 Sierra Point Parkway, Suite 1200, Brisbane, California 94005.

**Item 4. Purpose of Transaction**

The Reporting Persons hold their securities of the Issuer for investment purposes.  Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners.  Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments.  Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person.  Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 71,355,667 shares of Common Stock outstanding as of February 23, 2026, as reported in the Issuer's Form 10-K (File No. 001-40407) filed with the Securities and Exchange Commission on February 26, 2026.

**(b)**
Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person.  Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person.  Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person.  Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.

**(c)**
Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

SVP X and Katabi have agreed that, without the prior written consent of Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C., on behalf of the Issuer's underwriters, they will not, subject to limited exceptions, during the period ending 180 days after the date set forth on the Prospectus, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for shares of Common Stock, or enter into any hedging, swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise.  Such Lock-Up Agreement is more fully described in the Prospectus and was filed as Exhibit A to Exhibit 1.1 to the Issuer's Amendment No. 1 to Form S-1 Registration Statement (File No. 333-255492), and such description is incorporated herein by reference.

SVP X is a party to a Second Amended and Restated Investors' Rights Agreement among the Issuer, SVP X and other shareholders.  Subject to the terms of such Second Amended and Restated Investors' Rights Agreement, SVP X can demand that the Issuer file a registration statement or request that its Common Stock be covered by a registration statement that the Issuer is otherwise filing under certain specified circumstances.  Such Second Amended and Restated Investors' Rights Agreement dated as of October 29, 2020 is more fully described in the Prospectus and was filed as Exhibit 4.2 to the Issuer's Form S-1 Registration Statement (File No. 333-255492), and such description is incorporated herein by reference.

Katabi, in her capacity as a director of the Issuer, along with the other directors of the Issuer, entered into an Indemnification Agreement with the Issuer.  Such Indemnification Agreement is more fully described in the Prospectus and was filed as Exhibit 10.8 to the Issuer's Amendment No. 1 to Form S-1 Registration Statement (File No. 333-255492), and such description is incorporated herein by reference.

In connection with the February 2023 Follow-on Offering, SVP X and Katabi have agreed that, without the prior written consent of J.P. Morgan, Cowen and Evercore, on behalf of the Issuer's underwriters, they will not, subject to limited exceptions, during the period ending 60 days after the date set forth on the 2023 Prospectus Supplement, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for shares of Common Stock,  enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of Common Stock, whether any such swap or transaction is to be settled by delivery of Common Stock, in cash or otherwise.  Such Lock-Up Agreement is more fully described in the 2023 Prospectus Supplement and was filed as Exhibit A to Exhibit 1.1 to the Issuer's Form 8-K (File No. 001-40407) filed on February 2, 2023, and such description is incorporated herein by reference.

In connection with the January 2024 Follow-on Offering, SVP X and Katabi have agreed that, without the prior written consent of J.P. Morgan, Cowen and Evercore, on behalf of the Issuer's underwriters, they will not, subject to limited exceptions, during the period ending 45 days and 60 days, respectively, after the date set forth on the 2024 Prospectus Supplement, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for shares of Common Stock,  enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of Common Stock, whether any such swap or transaction is to be settled by delivery of Common Stock, in cash or otherwise.  Such Lock-Up Agreement is more fully described in the 2024 Prospectus Supplement and was filed as Exhibit A to Exhibit 1.1 to the Issuer's Form 8-K (File No. 001-40407) filed on January 30, 2024, and such description is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Venture Partners X, L.P. ("SVP X")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber / Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management X, L.P. ("SM X LP")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber / Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management X-A, L.L.C. ("SM X LLC")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber / Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. James I. Healy ("Healy")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber / Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. Maha Katabi ("Katabi")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber / Attorney-in-Fact

**Date:** 03/05/2026